Allogene Therapeutics (ALLO) Income from Non-Controlling Interests (2018 - 2026)
Allogene Therapeutics (ALLO) reported Income from Non-Controlling Interests of -$452000.0 for Q1 2026, down 442.42% on a YoY basis from $132000.0 in Q1 2025, and down 1429.41% sequentially from $34000.0 in Q4 2025.
Allogene Therapeutics (ALLO) Income from Non-Controlling Interests (2018 - 2026) Analysis & Trends
Allogene Therapeutics (ALLO) has 9 years of Income from Non-Controlling Interests data on file, last reported at -$452000.0 in Q1 2026.
- For the quarter ending Q1 2026, Income from Non-Controlling Interests fell 442.42% year-over-year to -$452000.0; the trailing twelve-month figure through Mar 2026 stood at -$226000.0 (down 123.3% YoY), and the FY2025 full-year result was $358000.0, down 58.66% from the prior year.
- Income from Non-Controlling Interests eased to -$452000.0 in Q1 2026, from $34000.0 in the prior quarter.
- In the past five years, Income from Non-Controlling Interests ranged from a high of $4.0 million in Q1 2023 to a low of -$6.7 million in Q1 2022.
- A 5-year average of $140235.3 and a median of $132000.0 in 2025 frame the typical range for Income from Non-Controlling Interests.
- Across the five-year window, Income from Non-Controlling Interests sank 2221.88% in 2022 and surged 371.43% in 2025, its largest moves.
- Tracing ALLO's Income from Non-Controlling Interests over 5 years: stood at $3.0 million in 2022, then slumped by 51.98% to $1.5 million in 2023, then tumbled by 116.9% to -$246000.0 in 2024, then surged by 113.82% to $34000.0 in 2025, then sank by 1429.41% to -$452000.0 in 2026.
- Business Quant data shows ALLO's Income from Non-Controlling Interests at -$452000.0 in Q1 2026, $34000.0 in Q4 2025, and $280000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | - |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Allogene Therapeutics | 437.33 Mn | 437.33 Mn | - | -452,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -452,000.00 |
| Dec 31, 2025 | 34,000.00 |
| Sep 30, 2025 | 280,000.00 |
| Jun 30, 2025 | -88,000.00 |
| Mar 31, 2025 | 132,000.00 |
| Dec 31, 2024 | -246,000.00 |
| Sep 30, 2024 | 937,000.00 |
| Jun 30, 2024 | 147,000.00 |
| Mar 31, 2024 | 28,000.00 |
| Dec 31, 2023 | 1.46 Mn |
| Sep 30, 2023 | 1.44 Mn |
| Jun 30, 2023 | 2.08 Mn |
| Mar 31, 2023 | 3.99 Mn |
| Dec 31, 2022 | 3.03 Mn |
| Sep 30, 2022 | -1.49 Mn |
| Jun 30, 2022 | -2.22 Mn |
| Mar 31, 2022 | -6.68 Mn |
| Dec 31, 2021 | -2.17 Mn |
| Sep 30, 2021 | -64,000.00 |
| Jun 30, 2021 | -233,000.00 |